United States
Redbud Labs, established in 2010, is at the forefront of the Biotechnology and Health Care sectors, offering innovative solutions in Manufacturing. Headquartered in the United States, the company specializes in Advanced Microfluidic Technologies.
Their flagship product, NAxtract, is an automated sample preparation platform that simplifies complex lab workflows with single-cartridge convenience. This cost-effective solution can process eight samples in just 30 minutes, making it particularly disruptive in markets such as liquid biopsy and genomic surveillance. Central to Redbud's innovation is their patented Redbud Post technology, which accelerates microfluidic sample prep significantly.
Boasting a comprehensive intellectual property portfolio with 18 patents granted and 36 pending, Redbud demonstrates a robust commitment to R&D. Their headquarters in Research Triangle Park, North Carolina, features nearly 8,000 sq.ft. of state-of-the-art lab space. The company's dedication to quality is evident through their ISO 9001 and 45001 certifications. Redbud's last funding was a grant investment received on 02 February 2021.
